FDA Approves Libtayo, 1st Immunotherapy for Advanced Basal Cell Carcinoma

FDA Approves Libtayo, 1st Immunotherapy for Advanced Basal Cell Carcinoma

286306

FDA Approves Libtayo, 1st Immunotherapy for Advanced Basal Cell Carcinoma

The U.S. Food and Drug Administration (FDA) has approved Libtayo (cemiplimab-rwlc), making it the first immunotherapy for people with advanced basal cell carcinoma (BCC) — the most common form of skin cancer — who previously received or were ineligible for treatment with a hedgehog pathway inhibitor. Based on the results of an ongoing Phase 2 trial, called Study 1620 (NCT03132636), the therapy was granted full approval for patients with locally advanced disease — cancer that…

You must be logged in to read/download the full post.